Exor N.V. (EXO)
Euronext Amsterdam · Netherlands · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 68.35 |
|---|---|
| 52-week range | 59.75 – 78.00 |
| Return, 1 month / 3 months | −4.3% / −1.7% |
| Return, 1 year / 3 years | −8.8% / −16.1% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 21.7% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 13.85M EUR |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Exor is an investment holding company controlled by the Agnelli family and based in the Netherlands. It owns and manages a portfolio of stakes in businesses across several industries, including motor vehicles through its interests in Ferrari and Stellantis, agricultural and construction equipment, reinsurance through PartnerRe, and professional football through Juventus. Exor acts as a long-term owner of these companies, holding positions in them and supporting their management rather than operating the businesses directly itself.
The shares are listed on the Euronext Amsterdam in Netherlands under the code EXO, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Exor N.V. (EXO) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 68.35 on 22 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 50 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 8.8% and over the last three months it fell 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.8% | ||
| From 52-week high | -11.7% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | -1.0% | ||
| 12-month return, skipping the last month | -4.7% | ||
| Stability (higher is calmer) | 76 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 75 · Strong | Trades actively. | |
| Average daily value traded | 13.85M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 11 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.4% |
|---|---|
| 1 month | −4.3% |
| 3 months | −1.7% |
| 6 months | −1.0% |
| 1 year | −8.8% |
| 3 years | −16.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 70.53 / 68.90 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.43 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 May 2026 | EUR 0.4900 |
| 26 May 2025 | EUR 0.4900 |
| 30 May 2024 | EUR 0.4600 |
| 2 Jun 2023 | EUR 0.4400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.